Nectar Lifescience Ltd vs Viyash Scientific Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 13, 2026

Key Highlights

The Latest Trading Price of Nectar Lifescience Ltd is ₹ 11.78 as of 12 Jun 15:30 . The P/E Ratio of Nectar Lifescience Ltd changed from 21.5 on March 2022 to 0 on March 2025 . This represents a CAGR of -100.00% over 4 yearsThe P/E Ratio of Viyash Scientific Ltd changed from 62.7 on March 2021 to 150.3 on March 2025 . This represents a CAGR of 19.11% over 5 years The Market Cap of Nectar Lifescience Ltd changed from ₹ 417.13 crore on March 2021 to ₹ 515.35 crore on March 2025 . This represents a CAGR of 4.32% over 5 yearsThe Market Cap of Viyash Scientific Ltd changed from ₹ 5983 crore on March 2021 to ₹ 3273 crore on March 2025 . This represents a CAGR of -11.36% over 5 years The revenue of Nectar Lifescience Ltd for the Mar '26 is ₹ 7.58 crore as compare to the Dec '25 revenue of ₹ 35.46 crore. This represent the decline of -78.62% The revenue of Viyash Scientific Ltd for the Mar '26 is ₹ 935.88 crore as compare to the Dec '25 revenue of ₹ 872.39 crore. This represent the growth of 7.28% The ebitda of Nectar Lifescience Ltd for the Mar '26 is ₹ -81.66 crore as compare to the Dec '25 ebitda of ₹ 33.53 crore. This represent the decline of -343% The ebitda of Viyash Scientific Ltd for the Mar '26 is ₹ 200.17 crore as compare to the Dec '25 ebitda of ₹ 148.35 crore. This represent the growth of 34.93% The net profit of Nectar Lifescience Ltd changed from ₹ 2.97 crore to ₹ -67.92 crore over 8 quarters. This represents a CAGR of NaN% The net profit of Viyash Scientific Ltd changed from ₹ 9.06 crore to ₹ 66.38 crore over 8 quarters. This represents a CAGR of 170.68% The Dividend Payout of Nectar Lifescience Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Viyash Scientific Ltd changed from 38.67 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 years .

About Nectar Lifescience Ltd

Nectar Lifescience Limited was initially incorporated on June 27, 1995 as 'Surya Medicare Limited'.
On March 26, 2004, Company changed the name from 'Surya Medicare Limited' to 'Nectar Lifescience Limited'.
NECLIFE is an integrated pharmaceutical organization, engaged in manufacturing and delivering high quality pharmaceutical products.
It is a global pharmaceutical company specializing in Cephalosporins.
Nectar excels in Cephalosporin APIs production with certified facilities meeting global standards.

About Viyash Scientific Ltd

Visistha Traders & Finance Ltd, has amalgamated PI Drugs & Pharmaceuticals Ltd with itself.
The High court has sanctioned the Scheme of Amalgamation and the same was filed with ROC by the company on Nov 12, 2003.

FAQs for the comparison of Nectar Lifescience Ltd and Viyash Scientific Ltd

Which company has a larger market capitalization, Nectar Lifescience Ltd or Viyash Scientific Ltd?

Market cap of Nectar Lifescience Ltd is 228 Cr while Market cap of Viyash Scientific Ltd is 10,919 Cr

What are the key factors driving the stock performance of Nectar Lifescience Ltd and Viyash Scientific Ltd?

The stock performance of Nectar Lifescience Ltd and Viyash Scientific Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Nectar Lifescience Ltd and Viyash Scientific Ltd?

As of June 14, 2026, the Nectar Lifescience Ltd stock price is INR ₹11.78. On the other hand, Viyash Scientific Ltd stock price is INR ₹249.95.

How do dividend payouts of Nectar Lifescience Ltd and Viyash Scientific Ltd compare?

To compare the dividend payouts of Nectar Lifescience Ltd and Viyash Scientific Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.